Venus Medtech wins Most Valuable Pharmaceutical and Medical Company Award at Golden Hong Kong Stocks

On January 11, 2022, Venus Medtech was awarded "Most Valuable Pharmaceutical and Medical Company" at the Global Investment Trends Forum and 6th Golden Hong Kong Stocks Awards Ceremony.

Winners of the 6th Golden Hong Kong Stocks Awards went through a rigorous selection spanning over three months. Eventually, 238 companies stood out from thousands of Hong Kong-listed candidates with a total worth of HKD 26 trillion. The candidates are engaged in both traditional industries such as petrochemicals, finance and automobile, and emerging industries that lead the transformation of the Chinese economy, such as semiconductor, Internet technology and biotechnology. As a result of rounds of screening, the awardees were selected by an expert committee based on their performance growth, industry ranking, corporate governance, business model, market influence and capital market performance in the past year.

The "Most Valuable Pharmaceutical and Medical Company" Award aims to honor HK-listed pharmaceutical and medical enterprises marked by effective corporate governance structure, prominent industry position, and satisfactory main business performance that provide sustainable and stable returns for investors. That the award was granted to Venus Medtech underlines the interests and attention of the healthcare industry and investors to innovative medical devices.

The 2022 Global Investment Trends Forum and 6th Golden Hong Kong Stocks Awards Ceremony was jointly organized by Zhitong Caijing and Tonghuashun Finance, leading Hong Kong and US stock information platforms in China, with roadshow support from Road showing, a professional financial roadshow live stream platform.

It is worth mentioning that this is the second time that Venus Medtech has won the award, as the Company received “Best Pharmaceutical and Medical Company” at the 2020 Forum. As China’s leader in transcatheter structural heart valvular therapies and the first company to launch NMPA-approved TAVR products nationwide, Venus Medtech has a significant first-mover advantage in the development and commercialization of innovative medical devices for structural heart disease. The Company has ongoing pipelines covering aortic valve, pulmonic valve, mitral valve, tricuspid valve and other heart valve diseases, hypertrophic cardiomyopathy, renal denervation for hypertension, and relevant accessory products. 

As an innovative Chinese enterprise, Venus Medtech enjoys a wealth of awards and honors, including the National Science and Technology Support Program Award under the 12th and 13th Five-Year Development Plans granted by the Ministry of Science and Technology of China, the second batch of State-Level Technologically Advanced Little Giant Enterprises, China Outstanding Patent Award, Excellent Domestic Medical Equipment Products and National High-Tech Enterprise. Innovation drives the future. At Venus Medtech, we will carry forward our commitment to the development and commercialization of innovative medical devices for structural heart disease, accelerating innovation in China and contributing to a better world.

Prev:Venus Medtech Concludes Acquisition of 100% Equity Interest in Cardiovalve

Next:Venus Medtech completes FIM clinical use of Venus-PowerX, the world’s first fully-released···